Deferasirox
Deferasirox belongs to iron chelators family. FDA approved it in November 2005. Deferasirox is the first drug approved in US for oral administration in the treatment of iron overload for anemia for the patients receiving blood transfusions. Iron chelators facilitate the removal of iron by making a bound with iron.
Primary Characteristics
It belongs to Chlelating agent pharmacological group on the basis of mechanism of action.
Molecular Weight: 373.36 · Non-proprietary name: Deferasirox.
Pharmacokinetics
Absorption: Deferasirox has an oral bioavailability is 70%.
Distribution: Deferasirox has a plasma protein binding is 99.
Elimination: plasma half-life is 8-6hr, renal excretion is 8%.
Advertisement
Indications
Deferasirox is primarily indicated in conditions like Blood transfusion, Chronic iron overload.
Contraindications
None recorded.
Dosage
Deferasirox's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 25 mg/kg | 25 mg/kg | Every 24h | ||
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Deferasirox is known to cause more or less tolerable side effects which are usually transient. These include Diarrhea, Nausea, Skin rash, Stomach pain, Vomiting .
Warnings / Precautions
Available Brands
Drug Classification
- 1.4.2.4 — Iron poisoning and iron & aluminium overload